TREATMENT PATTERNS AND GLYCEMIC OUTCOMES OF REAL-WORLD SGLT2-INHIBITORS BASED THERAPIES IN TYPE 2 DIABETES: A MULTICENTRIC STUDY FROM INDIA
DOI:
https://doi.org/10.22159/ajpcr.2026v19i1.57591Keywords:
Type 2 diabetes mellitus, SGLT2 inhibitors, Remogliflozin, Dapagliflozin, HbA1c reduction, Real-world studyAbstract
bjectives: This study aimed to describe the real-life use of sodium-glucose cotransporter-2 (SGLT2) inhibitor-based therapies as well as assess their effect on glycated hemoglobin (HbA1c) levels in individuals with type 2 diabetes mellitus (T2DM).
Methods: A prospective observational study was carried out from 6 diabetes centers (five in Pune, Maharashtra, and one in Trichy, Tamil Nadu). A total of 500 adults whose diabetes was being treated with an SGLT2 inhibitor alone or in combination with other antidiabetic drugs were enrolled. Treatment details, baseline characteristics, and HbA1c values at enrollment and at 26 weeks were recorded. Changes in HbA1c were reported using descriptive statistics and appropriate comparative statistical tests in the computer package, Version 26 of the software package, the Statistical Package for Social Sciences.
Results: The mean HbA1c at baseline was 8.93±1.8% which was reduced to 7.36±1.4% at 26 weeks of therapy (mean reduction: 1.57%, p<0.0001). Combination of such agents as Remogliflozin+Vildagliptin+Metformin+Sitagliptin (mean HbA1c reduction: −25.9±21.6%) and Dapagliflozin + Sitagliptin + Metformin (−26.5±8.4%) resulted in marked improvements. Overall, almost 72% of the therapeutic regimens resulted in a decrease in HbA1c of more than 0.5%.
Conclusion: In routine clinical practice, SGLT2 inhibitor-based treatments particularly when combined with dipeptidyl peptidase-4 inhibitors and metformin were associated with meaningful and consistent reduced HbA1c among Indian patients with T2DM.
Downloads
References
1. International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels: International Diabetes Federation; 2017.
2. Indian Council of Medical Research. ICMR Guidelines for Management of Type 2 Diabetes Mellitus. New Delhi: ICMR; 2018.
3. Shah A, Kanaya AM. Diabetes and associated complications in the South Asian population. Curr Cardiol Rep. 2014;16(5):476.
4. Mohan V, Tandon N. ICMR guidelines for management of type 2 diabetes 2018: Summary and implementation strategy. J Assoc Physicians India. 2019;67(2):44-50.
5. Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-95. doi: 10.2337/db09-9028, PMID 19336687
6. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-28. doi: 10.1056/ NEJMoa1504720, PMID 26378978
7. Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-57. doi: 10.1056/ NEJMoa1611925, PMID 28605608
8. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-57. doi: 10.1056/NEJMoa1812389, PMID 30415602
9. Research Society for the Study of Diabetes in India (RSSDI). Nutrition guidelines for individuals with type 2 diabetes mellitus. Int J Diabetes Dev Ctries. 2025;45(4):1119-324. doi: 10.1007/s13410-025-01502-0
10. Ferrannini E, Muscelli E. Renal glucose handling and SGLT2 inhibition. Diabetes. 2011;60(3):787-95.
11. Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol (Lausanne). 2019;10:389. doi: 10.3389/fendo.2019.00389, PMID 31275246
12. Nauck MA, Müller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023;66(10):1780-95. doi: 10.1007/s00125-023- 05956-x, PMID 37430117
13. Xie X, Wu C, Hao Y, Wang T, Yang Y, Cai P, et al. Benefits and risks of drug combination therapy for diabetes mellitus and its complications: A comprehensive review. Front Endocrinol (Lausanne). 2023;14:1301093. doi: 10.3389/fendo.2023.1301093, PMID 38179301
14. Yu M, Wang T, Xu C, Bi Y, Gao L, Wang G, et al. Triple oral therapy with metformin, DPP-4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025). Diabetes Obes Metab. 2025;27 Suppl 9:3-17. doi: 10.1111/dom.70197, PMID 41084961
15. Abdul-Ghani MA, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT): A randomized trial. Diabetes Obes Metab. 2015;17(3):268-75. doi: 10.1111/dom.12417, PMID 25425451
16. Nyström T. Key results from observational studies and real-world evidence of sodium-glucose cotransporter-2 inhibitor effectiveness and safety in reducing cardio-renal risk. Diabetes Obes Metab. 2024;26 Suppl 5:35-57. doi: 10.1111/dom.15696, PMID 38859661.
17. Tang H, Cui W, Li D, Wang T, Zhang J, Zhai S, et al. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(1):142-7. doi: 10.1111/ dom.12785, PMID 27598833
18. Yang Y, Chen S, Pan H, Zou Y, Wang B, Wang G, et al. Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials. Med (Baltimore). 2017;96(21):e6944. doi: 10.1097/ MD.0000000000006944, PMID 28538386
19. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43. doi: 10.1186/1741-7015-11-43, PMID 23425012
20. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Ann Intern Med. 2012;156(6):405-15. doi: 10.7326/0003-4819-156-6-201203200- 00003, PMID 22431673
21. Pinto OS, Shetty R, Faizal UY, Sayish A, Chacko CT, Shabaraya AR. Hospital-based study to assess the effectiveness and safety of antidiabetic monotherapy in contrast to combination therapy. Int J Curr Pharm Res. 2025;17(6):112-21. doi: 10.22159/ijcpr.2025v17i6.8004
22. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2018;41(12):2669-701. doi: 10.2337/dci18-0033, PMID 30291106
23. Matthews DR, Paldánius PM, Proot P, Chiang YT, Stumvoll M, Del Prato S, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 2019;394(10208):1519-29.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Bharat Kshirsagar
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.